• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
European Head and Neck Cancer Therapeutics Markets Product Image

European Head and Neck Cancer Therapeutics Markets

  • ID: 550274
  • August 2007
  • Region: Europe
  • 124 Pages
  • Frost & Sullivan

This Frost & Sullivan research service titled European Head and Neck Cancer Therapeutics Markets provides market drivers, restraints and revenue forecasts for this market. In this research, Frost & Sullivan's expert analysts thoroughly examine the chemotherapy and targeted therapies markets.

Targeted Therapy Improves Survival Rates among Patients with Head and Neck Cancer

Physicians in Europe are eager for novel therapies for head and neck cancer, as five-year survival rates among patients have remained low at 33.0 per cent for decades. Some of the new drugs that fall under targeted therapies have eliminated the shortcomings of traditional chemotherapy treatment by predominantly acting only on the cancer cells and leaving the healthy cells intact. These drugs achieve this precision by interfering with specific molecules involved in carcinogenesis and tumour growth. "An example of targeted therapy is Erbitux (cetuximab), a first in class IgG1 monoclonal antibody (mAb), specifically targeting the epidermal growth factor receptor (EGFR)," says the analyst of this research service. "mAbs are highly specific therapeutics and have improved side effects profiles."

Most READ MORE >

Note: Product cover images may vary from those shown

1. Executive Summary
-1. Overview
--1. Overview of the Head and Neck Cancer Therapeutics Market

2. Glossary of Terms
-1. List of Terms
--1. Abbreviations

3. Market Overview
-1. Introduction
--1. Disease Characteristics
--2. Epidemiology
-2. Market Definition and Segmentation
--1. Definition
--2. Segmentation

4. Research Methodology
-1. Research Objectives and Scope
--1. Methodology
--2. Assumptions and Limitations

5. Industry Challenges
-1. Industry Challenges for the European Head and Neck Cancer Therapeutics Markets
--1. Challenges Faced by Pharmaceutical Companies

6. Total European Head and Neck Cancer Therapeutics Market
-1. Overview and Definitions
--1. Introduction
--2. Market Drivers
---a. Unmet needs offer scope for new treatment options
---b. Targeted therapy broadens treatment opportunities
---c. Combination therapies setting new standards of care for adjuvant therapy
---d. Earlier diagnosis due to increasing awareness
---e. Higher incidence of head and neck cancer increasing market potential
--3. Market Restraints
---a. High cost of targeted therapies limit uptake
---b. Lower incidence rates compared to other diseases limits R&D expenditure
---c. Fewer medicines in development for cancer than other diseases
---d. Patent expiries of generics increase pressure on pharma companies
--4. Current Therapeutic Options
--5. Future Therapeutic Approaches
--6. Current Treatment Guidelines
--7. Pricing Trends
--8. Market Engineering Measurement Analysis
-2. Competitive Analysis
--1. Profiles of Key Industry Participants and Market Share Analysis
--2. Pipeline Analysis

7. Total Forecasts for the European Head and Neck Cancer Therapeutics Market
-1. Forecasts
--1. Patient Forecasts
--2. Market Revenue Forecasts
--3. Geographical Trends
--4. Forecasts of Recent Entrants - Erbitux

8. Pricing and Reimbursements
-1. Pricing and Reimbursement Issues
--1. Pricing and Reimbursement

9. Strategic Recommendations for the European Head & Neck Cancer Therapeutics Market
-1. Market Engineering Recommendations
--1. Strategic Recommendations

10. Database of Key Industry Participants
-1. Key Industry Participants
--1. Key Participants in the Head and Neck Cancer Therapeutics Market

11. Decision Support Databases
-1. Habitual Indicators
--1. Prevalence of Smokers
--2. Prevalence of Male Smokers
--3. Prevalence of Female Smokers
--4. Alcohol Consumption
-2. Healthcare Expenditure
--1. Expenditure
--2. Pharmaceutical R&D Expenditure
-3. Demography
--1. Female Population Aged 65 Years and Above
--2. Male Population Aged 65 Years and Above
--3. Population Aged 65 Years and Above
--4. Percent of Population Aged 65 Years and Above

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos